Published in Gene Therapy Weekly, April 17th, 1995
The biotechnology company received an exclusive license for the patent from the U.S. National Institutes of Health (NIH), but it isn't clear how valuable the patent will be to the small company, since it may be years before anyone can commercialize the technique.
Brandon Fradd, an analyst with Montgomery Securities in San Francisco, California, said the breadth of the patent helped drive up the company's shares,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.